|1.||Allaire, C: 3 articles (12/2005 - 08/2001)|
|2.||Maruyama, Katsuhiko: 2 articles (08/2006 - 01/2006)|
|3.||Shirato, Shiroaki: 2 articles (08/2006 - 01/2006)|
|4.||Ozdemir, Murat: 2 articles (03/2004 - 01/2003)|
|5.||Ozdemir, Gokhan: 2 articles (03/2004 - 01/2003)|
|6.||Trinquand, C: 2 articles (02/2003 - 08/2001)|
|7.||Pang, Yu-ying: 1 article (04/2013)|
|8.||Li, Yi-xin: 1 article (04/2013)|
|9.||Yao, Bao-qun: 1 article (04/2013)|
|10.||Takahashi, Atsushi: 1 article (09/2012)|
03/01/1988 - "During an open multicenter field study the new beta-blocking agent Carteolol, in 1% and 2% solution, proved to be effective and safe in the treatment of 178 patients suffering from glaucoma. "
01/01/1988 - "The effect of topical carteolol 2% on the intraocular pressures of 12 patients suspected of having glaucoma was measured in a double-crossover trial of six weeks' duration. "
02/01/2010 - "[The influence of carteolol and pentoxyphylin on the visual field in glaucoma patients--case reports of selected patients]."
12/01/2005 - "Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients."
05/01/2000 - "In vitro, carteolol has a marked vasorelaxing effect on porcine ciliary arteries, however the clinical relevance of this observation for the care of glaucoma patients requires further evaluation."
|2.||Hypertension (High Blood Pressure)
01/01/1986 - "Carteolol treatment of essential hypertension: a long-term study of safety and efficacy."
01/01/1983 - "The ability of 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) to lower the blood pressure was tested in an open clinical study on 66 patients with I-III degree essential hypertension. "
03/01/1990 - "The results suggest that long-term use of low doses of carteolol may reduce blood pressure without affecting circulatory regulatory functions, even in elderly patients with mild hypertension."
03/01/1990 - "Circulatory autonomic functions and resting and exercise hemodynamics were studied before and six months after daily administration of 5 mg of carteolol in seven elderly patients with mild hypertension. "
03/01/1990 - "Effects of long-term treatment with low doses of carteolol on cardiovascular regulatory functions in elderly patients with mild hypertension."
|3.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
06/01/1991 - "This study suggests that carteolol prevents the development of myocardial lesions similar to those in dilated cardiomyopathy after myocarditis in the chronic stage."
11/01/2001 - "We have shown that chronic treatment with carteolol, a non-selective beta-adrenergic receptor antagonist, improved left ventricular (LV) function and survival in an avian model of dilated cardiomyopathy (DCM). "
04/01/1992 - "A nonselective beta-adrenergic blocker with intrinsic sympathomimetic activity, carteolol, prevented the development of myocardial lesions similar to those in dilated cardiomyopathy after myocarditis in the chronic stage."
03/02/1999 - "Beneficial effects of alpha1-adrenergic blocking agents, carteolol, verapamil, and ACE inhibitors have been shown clinically and experimentally in the treatment of viral myocarditis and dilated cardiomyopathy. "
06/01/1991 - "The effects of carteolol, a nonselective beta-adrenergic receptor blocker with intrinsic sympathomimetic activity, were compared with those of metoprolol in a murine model of viral myocarditis and dilated cardiomyopathy caused by encephalomyocarditis virus. "
01/01/1986 - "Carteolol was shown to be effective and safe when administered on a long-term basis to patients with angina pectoris."
01/01/1986 - "Seventy-two patients entered the treatment phase of an open, long-term, dose-ranging trial of carteolol in stable, exercise-induced angina pectoris. "
01/01/1983 - "The treatment of angina pectoris with the new beta-receptor blocker carteolol. "
07/01/1988 - "In a multicenter, dose-ranging, double-blind study, 63 patients diagnosed as having stable angina pectoris were randomly assigned to treatment with carteolol (33 patients) or nadolol (30 patients). "
07/01/1988 - "A comparison of carteolol and nadolol in the treatment of stable angina pectoris."
02/15/1989 - "However, in patients with spontaneous sinus bradycardia carteolol increased lowest heart rate (+14%, due to overriding ISA) and lowered exercise heart rate (-15%, due to overriding beta blockade). "
02/15/1989 - "In patients with previous beta blocker induced bradycardia, carteolol did not change a normal resting heart rate off treatment. "
02/15/1989 - "A beta blocker induced sinus bradycardia consistently improved with change of treatment to carteolol and pindolol. "
10/01/1997 - "Systemic and ocular signs and symptoms were similar between the groups except that the number of treatment-emergent reports of bradycardia was greater in the timolol maleate group (P = .039), and the carteolol group reported fewer ocular symptoms than the timolol maleate group did (P < .01). "
02/15/1989 - "With caution carteolol and pindolol may also be used despite spontaneous sinus bradycardia."
|1.||Pindolol (LB 46)
|4.||Adrenergic Receptors (Adrenergic Receptor)
|6.||Dopamine Receptors (Dopamine Receptor)
|10.||Ophthalmic Solutions (Eye Drops)